

5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 5

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III EMBER-3 study evaluated which experimental treatment for patients with HR-positive, HER2-negative advanced breast cancer after disease progression on prior endocrine therapy?**

 - Elacestrant monotherapy
 - Elacestrant with abemaciclib
 - Imlunestrant monotherapy
 - Imlunestrant with abemaciclib
 - Both a and b
 - Both c and d
- 2. What was the investigator-assessed median progression-free survival (PFS) for patients with an ESR1 mutation who received imlunestrant monotherapy in the EMBER-3 study?**

 - 1.2 months
 - 2.5 months
 - 5.5 months
 - 9.7 months
- 3. Which of the following PFS outcomes was reported comparing the monotherapy and combination treatment arms in the EMBER-3 study?**

 - Inferior PFS with the combination
 - No significant difference in PFS
 - Superior PFS with the combination
- 4. What was the approximate rate of discontinuation due to an adverse event among patients receiving the combination treatment in the EMBER-3 study?**

 - 6%
 - 12%
 - 25%
 - 38%
- 5. In a subgroup analysis of elacestrant in the Phase III EMERALD study, what was the approximate median PFS for patients who had received at least 12 months of prior endocrine therapy with a CDK4/6 inhibitor?**

 - 1.91 months
 - 3.12 months
 - 5.58 months
 - 8.61 months